📌 Groundbreaking insights from Dr. Sabine Hazan on Ivermectin

Groundbreaking insights from Dr. Sabine Hazan on Ivermectin, Bifidobacteria, and the microbial origins of medicine.
.
Dr. Sabine Hazan, a leading microbiome researcher and author of Let's Talk SHT*, recently shared a paradigm-shifting perspective on the connections between ivermectin, bifidobacteria, and the microbial foundations of modern drugs.
.
Her discoveries, rooted in clinical observations during the COVID-19 pandemic, challenge conventional views of pharmaceuticals and highlight the critical role of the gut microbiome in health.
.
The Ivermectin Revelation: While treating patients, Dr. Hazan noticed that ivermectin appeared to improve oxygen saturation in severe COVID cases. This led to a stunning hypothesis: ivermectin, a drug derived from the fermented secretions of soil bacteria (Streptomyces avermitilis), may be linked to bifidobacteria, a keystone gut microbe.
.
Bifidobacteria, abundant in infants but often deficient in severe COVID patients and the elderly, could be central to immune health. Dr. Hazan posits that ivermectin’s effects might involve supporting or mimicking bifidobacteria’s role in the gut.
.
Microbes as Medicine: Dr. Hazan’s research reframes how we view drugs. Antibiotics, she explains, originate from microbes battling microbes. Take penicillin: discovered when mold from a mildewed apple killed bacteria in a petri dish, later scaled up using mildewed watermelon.

Similarly, vaccines are microbial fragments—dead or alive—that train the immune system. Even peptides, now gaining popularity, are proteins extracted from sources like breast milk or bovine immunoglobulins. Ivermectin fits this pattern as a microbial byproduct with potential immune-modulating effects.

Bifidobacteria at the Core: Dr. Hazan’s work centers on bifidobacteria as a cornerstone of immunity. She observed that severe COVID patients often lack this microbe, and her research explores whether ivermectin’s benefits stem from its interaction with the gut microbiome.

Could ivermectin’s bacterial origins enable it to restore microbial balance, much like fecal transplants suppress C. difficile by introducing beneficial bacteria? This question drives her ongoing studies.

A Call to Rethink Drugs: In Let's Talk SHT*, Dr. Hazan traces the microbial roots of medicine, urging us to see drugs not as synthetic miracles but as products of nature’s microbial wars.

Her insights challenge us to explore how therapies like ivermectin might work by nurturing our microbiome, potentially unlocking new approaches to treating disease.

Why It Matters: Dr. Hazan’s discoveries highlight the gut microbiome’s untapped potential in medicine. By connecting ivermectin to bifidobacteria, she opens new avenues for research into immunity, aging, and chronic disease. Her work reminds us that the answers to modern health challenges may lie in the ancient interplay of microbes.